New York University Skip to Content Skip to Search Skip to Navigation Skip to Sub Navigation

Chemists Find New Way to Put the Brakes on Cancer

September 9, 2013
10

While great strides have been achieved in cancer treatment, scientists are looking for the new targets and next generation of therapeutics to stop this second leading cause of death nationwide. A new platform for drug discovery has been developed through a collaborative effort linking chemists at NYU and pharmacologists at USC.

In a study appearing in Proceedings of the National Academy of Sciences, the research groups of Paramjit Arora, a professor in NYU’s Department of Chemistry, and Bogdan Olenyuk from the USC School of Pharmacy have developed a synthetic molecule, “protein domain mimetic,” which targets the interaction between two proteins, called transcription factor-coactivator complex at the point where intracellular signaling cascade converges resulting in an up-regulation of genes that promote tumor progression.

This approach presents a new frontier in cancer research and is different from the typical search for small molecules that target cellular kinases.

The synthetic molecule that the paper describes -- HBS 1 -- is based on chemically stabilized secondary structure of a protein that is mimicking specific fold, called α-helix ,- and shows outstanding potential for suppression of tumor growth. This compound was specifically designed to interrupt the type of molecular conversation within cell (called cell signaling) that promotes growth of cancer cells. Creation of HBS 1 required a method for locking correct helical shapes in synthetic strings of amino acids – a method previously developed at NYU.

The studies conducted at NYU and USC show that the molecule disrupted the cancer cell signaling network and reached the correct target in the cell to provide a rapid blockade of tumor growth. Importantly, the compounds did not show any signs of toxicity or negative impact in the test host.

While the in vivo experiments in this research were conducted using renal carcinoma cells, the principles of this design are applicable to many human conditions, including other cancers, cardiovascular diseases, and diabetic complications. The general concept of the study, the interruption of the connection between genes as they conspire to promote cancer growth, is general and applicable to the protein cell to protein cell “conversations” implicated in a host of human diseases.

Next, the NYU and USC teams will initiate the translational aspects of the project. The compounds will be tested in advanced tumor models, with the aim to ultimately take the compound into clinical trials. In addition to the lead authors on the paper, contributors include Ramin Dubey and Hanah Mesallati from USC and Brooke Bullock Lao, Laura K. Henchey, and Nathaniel J. Traaseth from NYU.

This research was supported by an NSF CAREER Award to Bogdan Olenyuk, and an NIH grant (R01GM073943) to Paramjit Arora.

This Press Release is in the following Topics:
Arts and Science, Research

Type: Press Release

Press Contact: James Devitt | (212) 998-6808

Chemists Find New Way to Put the Brakes on Cancer

Researchers from NYU and USC have developed a new platform for drug discovery--a synthetic molecule, “protein domain mimetic,” which targets the interaction between two proteins (depicted above)--that has implications for cancer research. The general concept of the study, the interruption of the connection between genes as they conspire to promote cancer growth, is applicable to the protein cell to protein cell “conversations” implicated in a host of human diseases. Image courtesy of Bogdan Olenyuk (University of Southern California).


Search News



NYU In the News

Entrepreneurship Lab Opens at NYU

Crain’s New York Business covered the opening of the Mark and Debra Leslie Entrepreneurial eLab, which will be the headquarters for NYU’s Entrepreneurial Institute and all of the University’s programs aimed at promoting innovation and startups.

A Globalizer for N.Y.U. in Abu Dhabi

The New York Times profiled Bill Bragin who will become the first executive artistic director of NYU Abu Dhabi’s new performing arts center.

Think Tank to Ponder a Future for Ballet

The New York Times profiled Jennifer Homans, the director of NYU’s new Center for Ballet and the Arts.

The Brilliant Ten: Jonathan Viventi Builds Devices That Decode Thoughts

Popular Science named Assistant Bioengineering Professor Jonathan Viventi as one of its “brilliant ten” for his research into brain implants that could one day halt epileptic episodes:

Living and Leaving the Dream: Adrian Cardenas’ Journey from the Major Leagues to College

The New York Times ran a feature on Adrian Cardenas, a former major league baseball player who is now studying philosophy and creating writing at NYU.

NYU Footer